|
Post by mytakeonit on Oct 5, 2017 13:59:39 GMT -5
I have a way to go for my break even. That r/s was such a disappointment. My hope is that once the ship is righted that a forward split will happen. So you are saying you want a reversed reverse split? That'll happen when we hit the $300 pps that Nate mentioned ... or the $400 pps that I increased it to. Anyone here knows Nate by any chance?
|
|
|
Post by dreamboatcruise on Oct 5, 2017 14:31:46 GMT -5
I have a way to go for my break even. That r/s was such a disappointment. My hope is that once the ship is righted that a forward split will happen. So you are saying you want a reversed reverse split? That'll happen when we hit the $300 pps that Nate mentioned ... or the $400 pps that I increased it to. Anyone here knows Nate by any chance? I thought someone here posted about him talking of a $27 target recently.
|
|
|
Post by factspls88 on Oct 5, 2017 14:35:05 GMT -5
Exactly.
|
|
|
Post by factspls88 on Oct 5, 2017 14:50:37 GMT -5
Big Pharmas are smart. Once they realize A has a good chance to redefine standard of care, no doubt they will swoop in, from my experience. They won't wait till script hits 5K/wk. Now that Novo popularized Fiasp Fast acting, made it sexy, fashionable, trendy, hip, glamorous, other Pharmas gonna trip over themselves to one up that. The only thing that handily beats Fiasp for bolus whether injectable or non injectable is A. A is mucho more sexy, fashionable, trendy, hip, glamorous, Hollywood, and effective than Fiasp ever dreams of, which sounds like Fiasco, btw. Despite all that, A is even more practical and cheaper. Let's not forget Mex, Can, U.S. Are NAFTA buddies. That means no tariff, low shipping cost (we share borders. no wall built yet), no refrigeration if used within 30 days. Of course, BoD (reversed shark tank) will play hard to get maybe accepting $0.5 B for 5% stake, or $10B valuation ($60 ish Pps). Thank you, Denmark, for your reversed Marshall plan. To imitate peppy, BPs would look at each other saying Oh chit, we can't let Fiasp dominate the fast acting bolus market, what we gonna do?? Developing Fiasp's Daddy from scratch would take at least $3B, 12 years to gain good FDA approval with no guarantee for success. You know what BPs would do as any smart biz people. The FDA said in no uncertain terms that Afrezza is the fastest acting insulin on the market. And Afrezza is not an injectable to boot. Afrezza has huge competitive advantage and as you point out a clear moat that will be costly and difficult to replicate and penetrate. And the frosting on top? A product that delivers non-diabetic numbers and enables users to live a near normal life with little fear of complications and devastating hypoglycemia. What more could you want in a product? Mike C. gets it and I believe he will deliver. I'm going nowhere and I am in this to win. I know that I may slip back into negative territory tomorrow but I believe it will be transitory - after this rough ride I think I can handle it. Good luck to all, no matter which path you choose.
|
|
|
Post by ilovekauai on Oct 5, 2017 14:51:00 GMT -5
Yes, I want a forward split down the line. We'll see.
|
|
|
Post by oldfishtowner on Oct 5, 2017 14:59:55 GMT -5
Big Pharmas are smart. Once they realize A has a good chance to redefine standard of care, no doubt they will swoop in, from my experience. They won't wait till script hits 5K/wk. Now that Novo popularized Fiasp Fast acting, made it sexy, fashionable, trendy, hip, glamorous, other Pharmas gonna trip over themselves to one up that. The only thing that handily beats Fiasp for bolus whether injectable or non injectable is A. A is mucho more sexy, fashionable, trendy, hip, glamorous, Hollywood, and effective than Fiasp ever dreams of, which sounds like Fiasco, btw. Despite all that, A is even more practical and cheaper. Let's not forget Mex, Can, U.S. Are NAFTA buddies. That means no tariff, low shipping cost (we share borders. no wall built yet), no refrigeration if used within 30 days. Of course, BoD (reversed shark tank) will play hard to get maybe accepting $0.5 B for 5% stake, or $10B valuation ($60 ish Pps). Thank you, Denmark, for your reversed Marshall plan. To imitate peppy, BPs would look at each other saying Oh chit, we can't let Fiasp dominate the fast acting bolus market, what we gonna do?? Developing Fiasp's Daddy from scratch would take at least $3B, 12 years to gain good FDA approval with no guarantee for success. You know what BPs would do as any smart biz people. The FDA said in no uncertain terms that Afrezza is the fastest acting insulin on the market. And Afrezza is not an injectable to boot. Afrezza has huge competitive advantage and as you point out a clear moat that will be costly and difficult to replicate and penetrate. And the frosting on top? A product that delivers non-diabetic numbers and enables users to live a near normal life with little fear of complications and devastating hypoglycemia. What more could you want in a product? Mike C. gets it and I believe he will deliver. I'm going nowhere and I am in this to win. I know that I may slip back into negative territory tomorrow but I believe it will be transitory - after this rough ride I think I can handle it. Good luck to all, no matter which path you choose. Exactly. It is Novo and Sanofi who are saying, Oh chit!
|
|
|
Post by brewguy on Oct 5, 2017 15:00:40 GMT -5
Congrats. According to our recent poll though many of us are still down at least 50% or more.
|
|
|
Post by silentknight on Oct 5, 2017 15:08:42 GMT -5
This week has been great, undoubtedly, and I think we may have received some new found attention from big pharma for the new label, but MNKD's success will still depend on the execution of Mike and Co. in how they proceed with their plan for the company. I'm reminded a lot of how exuberant we were after FDA approval all those years ago. There's lots of reason to celebrate, no doubt, but I'm in this for the long term and I want MNKD to really knock everything out of the park. Script numbers need to keep going up, significantly up, and efforts have to be made to expand internationally and move the pipeline forward. I'm confident Mike is doing that, but he needs to keep delivering. The good news is that with his options, Mike could sell today and be very well off. I think he has an incentive to keep pushing for success and I'll be more than happy to ride his coat tails all the way to an early retirement if he keeps things moving in the right direction.
|
|
|
Post by dreamboatcruise on Oct 5, 2017 15:27:13 GMT -5
This week has been great, undoubtedly, and I think we may have received some new found attention from big pharma for the new label, but MNKD's success will still depend on the execution of Mike and Co. in how they proceed with their plan for the company. I'm reminded a lot of how exuberant we were after FDA approval all those years ago. There's lots of reason to celebrate, no doubt, but I'm in this for the long term and I want MNKD to really knock everything out of the park. Script numbers need to keep going up, significantly up, and efforts have to be made to expand internationally and move the pipeline forward. I'm confident Mike is doing that, but he needs to keep delivering. The good news is that with his options, Mike could sell today and be very well off. I think he has an incentive to keep pushing for success and I'll be more than happy to ride his coat tails all the way to an early retirement if he keeps things moving in the right direction. I think we have no way of knowing. Granted I'm sure the product managers for competing prandials have probably read the new Afrezza label... but is this news that is going to be rushed into the C-suite, ehh, don't know about that.
|
|
|
Post by sportsrancho on Oct 5, 2017 16:24:01 GMT -5
Somebody knows something! Lol All those options were bought before the stock ran:-)
Iām 170% over even. And my old dead 2018 calls are green.
|
|
|
Post by falconquest on Oct 5, 2017 17:07:45 GMT -5
We need a good scripts number tomorrow to keep our gains. This rally is still in the ābuying the rumorā stage. I have a huge number of shares at a much higher price. Iāll start celebrating when weāre in the 30s. Iāll feel investing in MNKD was āworth itā when Afrezza is projected to do 1 billion in sales. My original expectation was 3 billion after a global launch. We still have a long way to go, but at least weāre moving in the right direction for the first time in years. We need to see if institutional buyers reenter the stock. Only then will this rally have legs. Bingo! I congratulate those who broke even but if we don't get good sales numbers look out! This will pull back at some point and it could fall hard if we don't get news to sustain the rally. Since there is no basis for the rally (that we know of other than label) we should all anticipate a huge bear raid that will allow shorts to exit. Of course this is only my opinion and since I have been wrong about Mannkind stock for so long I would take it with a grain of salt.
|
|
|
Post by mytakeonit on Oct 5, 2017 17:10:25 GMT -5
Somebody knows something! Lol All those options were bought before the stock ran:-) Iām 170% over even. And my old dead 2018 calls are green. Alright! Drinks are on sports !!!
|
|
|
Post by sportsrancho on Oct 5, 2017 17:32:55 GMT -5
Somebody knows something! Lol All those options were bought before the stock ran:-) Iām 170% over even. And my old dead 2018 calls are green. Alright! Ā Drinks are on sports !!! Well that works out for you since youāre buying the Gambling Cowboy:-)))
|
|
|
Post by mytakeonit on Oct 5, 2017 17:33:50 GMT -5
Okay ... then dinner on me!
|
|
|
Post by sophie on Oct 5, 2017 17:36:27 GMT -5
Years in the making š . Congrats!
|
|